Clinical Trial Update: Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 pharmacogenomic study of neoadjuvant eribulin in HER2 non-overexpressing breast cancer. The study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED